Ionis Pharmaceuticals, Inc. Common Stock
IONS
$47.25
-8.15%
Ionis Pharmaceuticals is the leading developer of antisense oligonucleotide technology, discovering and commercializing novel RNA-targeted drugs across cardiovascular, metabolic, neurological, and rare disease areas, with a commercial portfolio that includes partnered products such as Biogen's Spinraza and Qalsody, AstraZeneca's Wainua, and its own independently launched Tryngolza and Dawnzera. The company is distinct as the platform originator in antisense, monetizing its pipeline through a hybrid model of royalty-generating partnerships and an emerging wholly-owned commercial franchise, which differentiates it from single-asset biotechs and royalty-only vehicles. The current investor narrative is dominated by the tension between platform validation and commercial execution: the FDA approval of Zanvastro for the ultra-rare brain disorder Alexander disease in September 2026 validated the technology but was widely viewed as commercially limited, while the July 2026 collapse in the share price — a roughly 30% single-session drawdown — refocused debate on Tryngolza's launch trajectory, competitive pressure from Arrowhead Pharmaceuticals, and the company's heavy cash burn. Bulls argue the pipeline optionality and 2025-2026 independent launches mark an inflection toward durable product revenue, while bears point to persistent losses, negative free cash flow, and the market's tepid reception to near-term catalysts.…
IONS
Ionis Pharmaceuticals, Inc. Common Stock
$47.25
Related headlines
Investment Opinion: Should I buy IONS Today?
The synthesized recommendation is Hold, reflecting a balance between the bullish analyst consensus and the significant near-term risks. The analyst consensus rating is Buy with a recommendation mean of 1.79, and the average target price of $84.23 implies 55.4% upside, but the wide target range from $54.00 to $105.00 signals high uncertainty. The core thesis is that Ionis's antisense platform is validated and offers long-term optionality, but the commercial execution and cash burn issues are likely to keep the stock range-bound until tangible revenue inflection is visible.
Supporting evidence includes the 86.98% year-over-year revenue growth in Q1 2026 to $246.09 million, a gross margin of 98.79%, and a current ratio of 3.83 indicating sufficient liquidity. However, the price-to-sales ratio of 13.41x and EV/Sales of 10.68x are well above the sector average of 5x-6x, and free cash flow is deeply negative at -$971.26 million TTM. The PEG ratio of 1.53 suggests that when growth is factored in, the valuation is not egregiously expensive, but this metric is fragile given the negative earnings base. The implied upside to the average analyst target is 55.4%, but the low target of $54.00 suggests limited downside from current levels.
Key risks that could invalidate the thesis include a failure to ramp Tryngolza and Dawnzera, competitive pressure from Arrowhead, and the need for additional financing. The rating would upgrade to Buy if product revenue accelerates and free cash flow trends improve, or if the stock breaks above the $63-$64 resistance level with strong volume. It would downgrade to Sell if revenue growth decelerates below 20% or if cash burn accelerates, leading to a break below the 52-week low of $50.01. Relative to its history and peers, the stock appears overvalued on a price-to-sales basis, but the pipeline optionality and analyst optimism provide support, making it fairly valued for a high-risk, high-reward biotech.
Sign up to view all
IONS 12-Month Price Forecast
The forward-looking view is neutral with medium confidence, balancing the potential for commercial inflection against significant cash burn and valuation risks. The stock is likely to remain volatile, with the base case suggesting a range of $65-$85 over 12 months. Key developments that would cause an upgrade include sustained product revenue growth and improved cash flow, while a downgrade would be triggered by commercial disappointments or a break below $50. The low beta of 0.419 means the stock is driven by company-specific news, making it suitable for event-driven investors rather than macro traders.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Ionis Pharmaceuticals, Inc. Common Stock's 12-month outlook, with a consensus price target around $83.82 and implied upside of +77.4% versus the current price.
Average Target
$83.82
0 analysts
Implied Upside
+77.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$54 - $105
Analyst target range
Coverage is robust with 22 analysts, and the consensus recommendation is Buy with a recommendation mean of 1.79 (where 1.0 is a strong buy and 5.0 a strong sell), indicating a clearly bullish tilt despite the stock's collapse. The average target price of $84.23 implies 55.4% upside from the current price of $54.21, a striking disconnect that suggests either the sell-side is anchored to pre-July valuation models or genuinely views the drawdown as an overreaction. The consensus leans bullish, but the magnitude of the implied upside — more than 55% — combined with the stock trading near its 52-week low is a classic signal of stale targets that have not yet been revised downward following the July crash and the tepid Zanvastro reception. The target range is extremely wide, from a low of $54.00 to a high of $105.00, a spread of $51.00 or roughly 94% of the current price, which signals very high uncertainty and weak conviction even within a bullish consensus. The high target of $105.00 assumes successful commercial ramps for Tryngolza and Dawnzera, Zanvastro contributing beyond its ultra-rare niche, and multiple expansion back toward prior peak valuations — essentially a full pipeline-success scenario. The low target of $54.00, which is almost exactly the current price, prices in continued losses, competitive pressure from Arrowhead, and the possibility that the independent commercial launches underdeliver, implying the downside case is already reflected in the market. Institutional ratings show a cluster of reiterations in early-to-mid July 2026 — RBC Capital at Outperform, Barclays at Overweight, Morgan Stanley at Overweight, and Buy ratings from Citigroup, Jefferies, Needham, Canaccord, and HC Wainwright — but notably these are reiterations rather than upgrades, and Goldman Sachs maintained a Neutral stance on June 25, suggesting the bullish camp is holding the line rather than adding conviction. The combination of a wide target spread, a heavily shorted float (short ratio of 9.2), and a beta of 0.419 implies that the stock is a high-event-risk, idiosyncratic bet where analyst targets should be treated as directional sentiment rather than precise price forecasts.
Bulls vs Bears: IONS Investment Factors
The bear case currently has stronger evidence due to the severe cash burn, negative free cash flow, and technical breakdown, but the bull case rests on platform validation and analyst optimism. The most important tension is whether the independent commercial launches of Tryngolza and Dawnzera can drive a durable revenue inflection before cash reserves are depleted. If product revenue fails to accelerate in the next two to three quarters, the stock could break below $50 and test new lows. Conversely, any positive commercial data or partnership milestone could trigger a short squeeze given the 9.2-day short ratio.
Bullish
- Analyst Consensus Buy with 55% Upside: 22 analysts rate IONS a Buy with a recommendation mean of 1.79, and the average target price of $84.23 implies 55.4% upside from the current $54.21. Even the lowest target of $54.00 is essentially at the current price, suggesting the downside is already priced in.
- Platform Validation via Zanvastro FDA Approval: The September 2026 FDA approval of Zanvastro for Alexander disease validates Ionis's antisense platform in a third independent commercial setting. While the ultra-rare market limits near-term revenue, it de-risks the technology for larger indications and supports partnership economics.
- Revenue Growth of 87% YoY in Q1 2026: Q1 2026 revenue of $246.09 million grew 86.98% year-over-year, driven by a mix of commercial ($107.81M), royalty ($58.32M), and product ($42.96M) revenue. This demonstrates the platform's ability to generate multiple revenue streams as partnered drugs mature.
- Exceptional Gross Margins Near 99%: Gross margin of 98.79% in Q1 2026 (gross profit of $243.11 million) reflects the high-margin nature of antisense therapeutics. Once operating expenses are leveraged, even modest revenue growth can drive significant profitability, as seen in Q2 2025's $123.55 million net income.
Bearish
- Severe Cash Burn and Negative Free Cash Flow: Free cash flow TTM is -$971.26 million, with Q1 2026 operating cash flow of -$792.82 million including a -$730.12 million working capital swing. Cash at the end of Q1 2026 was only $173.38 million, down from $372.26 million at year-end 2025, necessitating external financing.
- Persistent Losses with No Clear Path to Profitability: Q1 2026 net loss was -$92.53 million (EPS -$0.56), with operating expenses of $360.53 million overwhelming revenue. R&D rose to $210.17 million and SG&A to $150.36 million, and with two independent launches ramping, losses may widen before they narrow.
- Extreme Valuation Relative to Peers: The price-to-sales ratio of 13.41x and EV/Sales of 10.68x are roughly 80-100% above the 5x-6x sector norm for commercial-stage biotechs. The price-to-book of 25.88x is extreme given negative ROE of -77.90%, implying the market is capitalizing pipeline optionality rather than current fundamentals.
- Technical Breakdown and Institutional Distribution: The stock trades just 5.2% above its 52-week low of $50.01, with a 40.15% maximum drawdown and relative underperformance versus SPY of -31.57 percentage points over one year. The July 2026 gap from $84.46 to $64.27 and further to $58.25 reflects persistent institutional selling.
IONS Technical Analysis
Ionis is in a clear and severe downtrend, with the current price of $54.21 sitting just 5.2% above its 52-week low of $50.01 and 37.5% below its 52-week high of $86.74, placing it in the bottom decile of its annual range. The 1-year price change of -15.35% understates the damage relative to the broader market, as the stock has underperformed SPY by 31.57 percentage points over the same period, and the 40.15% maximum drawdown confirms a sustained capital-destruction phase rather than a garden-variety pullback. Trading this close to the 52-week low signals a falling-knife setup where value-oriented buyers must weigh mean-reversion potential against the risk of a fresh breakdown below $50. Momentum is decisively negative and, critically, decelerating rather than stabilizing: the 1-month change of -4.10%, 3-month change of -26.02%, and 6-month change of -23.85% show the sharpest damage occurred in the last quarter, anchored by the July 2026 gap from $84.46 on July 8 to $64.27 on July 9 and further to $58.25 on July 10. The stock's relative strength versus SPY is negative across every window — -3.04 over 1 month, -29.06 over 3 months, and -44.04 year-to-date — indicating persistent institutional distribution rather than a temporary sentiment dip. The recent bounce from the $51.77 low on July 31 to $63.57 on August 25 has since failed, with the price rolling back to $54.21, suggesting the August rally was a counter-trend move within a larger downtrend. Key technical levels are well defined: support rests at the 52-week low of $50.01, and a decisive break below that level would likely trigger momentum-driven selling and open a new leg lower, while resistance sits at the 52-week high of $86.74, with intermediate resistance around the $63-$64 area where the August rally stalled. The beta of 0.419 is a notable anomaly for a biotech — it implies the stock moves only about 42% as much as the market, meaning the -31.57% relative underperformance over one year is driven almost entirely by idiosyncratic, company-specific factors (clinical, commercial, and financing news) rather than macro beta exposure, which argues for position sizing based on event risk rather than index correlation. The short ratio of 9.2 days-to-cover indicates a heavily shorted float, which cuts both ways: it amplifies downside on negative catalysts but creates squeeze potential on any positive surprise.
Beta
0.42
0.42x market volatility
Max Drawdown
-45.4%
Largest decline past year
52-Week Range
$47-$87
Price range past year
Annual Return
-22.7%
Cumulative gain past year
| Period | IONS Return | S&P 500 |
|---|---|---|
| 1m | -17.5% | -2.4% |
| 3m | -36.4% | +2.2% |
| 6m | -33.7% | +14.8% |
| 1y | -22.7% | +14.6% |
| ytd | -40.7% | +11.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IONS Fundamental Analysis
Revenue is lumpy and partnership-dependent rather than smoothly compounding: Q1 2026 revenue of $246.09 million grew 86.98% year-over-year against Q1 2025's $131.61 million, but that comparison flatters the trend because the prior-year base was depressed, and the sequential path shows Q2 2025 at $452.05 million, Q3 2025 at $156.72 million, Q4 2025 at $203.00 million, and Q1 2026 at $246.09 million — a pattern dominated by milestone and collaboration timing rather than steady product ramp. The revenue mix of $107.81 million commercial, $58.32 million royalty, and $42.96 million product revenue shows the business still leans heavily on partnered economics, with royalty and commercial payments from Biogen, AstraZeneca, and others exceeding the $42.96 million generated by Ionis's own products, which underscores that the independent commercial story remains early-stage. For the investment case, the 86.98% YoY growth is real but low-quality in the sense that it is not yet driven by a durable, self-sustaining product base, leaving the equity hostage to pipeline readouts and partner decisions. Profitability remains elusive despite exceptional gross margins: Q1 2026 gross margin was 98.79% (gross profit of $243.11 million on $246.09 million of revenue), yet net income was -$92.53 million and operating income was -$117.42 million, because operating expenses of $360.53 million — including $210.17 million of R&D and $150.36 million of SG&A — overwhelm the top line. The net margin of -40.36% and operating margin of -40.47% confirm that the company is spending roughly $1.47 for every $1.00 of revenue, and the quarterly EPS of -$0.56 extends a loss streak that includes -$1.41 in Q4 2025 and -$0.80 in Q3 2025, with the only recent profitable quarter being Q2 2025's $123.55 million net income (driven by a $452.05 million revenue spike). The trajectory is not toward near-term profitability: R&D of $210.17 million in Q1 2026 rose from $200.76 million in Q1 2025, and with two independent launches (Tryngolza, Dawnzera) plus Zanvastro commercialization ramping, SG&A of $150.36 million is likely to climb further, meaning losses may widen before they narrow. The balance sheet carries meaningful leverage and severe cash burn: debt-to-equity of 5.35 and a debt ratio of 0.59 reflect a capital structure where total debt is roughly 80.6% of total capitalization, and free cash flow TTM of -$971.26 million against Q1 2026 operating cash flow of -$792.82 million (including a -$730.12 million working capital swing) shows the company is consuming cash at an alarming rate. Liquidity is the offsetting strength — a current ratio of 3.83 and quick ratio of 4.09 provide a buffer — but cash at the end of Q1 2026 was only $173.38 million, down from $372.26 million at year-end 2025, and the company relied on $57.30 million of common stock issuance in the quarter plus investment maturities of $752.82 million to fund operations. ROE of -77.90% and ROA of -12.43% confirm that capital is being destroyed, and with FCF per share of -$4.94, Ionis depends on external financing and partnership milestones to fund its pipeline — a structural risk if capital markets tighten or a partner walks away.
Quarterly Revenue
$246091000.0B
2026-03
Revenue YoY Growth
+87.0%
YoY Comparison
Gross Margin
98.8%
Latest Quarter
Free Cash Flow
$-971257000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IONS Overvalued?
Because Ionis reported negative net income (EPS of -$0.03 on a trailing basis and -$0.56 in the most recent quarter), the PE ratio is not meaningful — the trailing PE of -33.24 and forward PE of -48.74 are both negative and therefore useless as valuation anchors — so the appropriate primary metric is the price-to-sales ratio, which stands at 13.41x trailing and 10.68x on an EV/Sales basis. The gap between the 13.41x trailing PS and the forward-looking revenue estimates implies the market expects substantial top-line growth: consensus estimated revenue of $3.16 billion against a current market cap of $12.66 billion produces a forward PS of roughly 4.0x, meaning the market is pricing in more than a tripling of revenue, which is an aggressive assumption that only holds if Tryngolza, Dawnzera, and Zanvastro ramp materially. The PEG ratio of 1.53 is the one positive valuation signal, suggesting that when growth is factored in, the stock is not egregiously expensive relative to its expected earnings trajectory — but this metric is fragile given the negative current earnings base. Relative to the biotechnology sector, Ionis's 13.41x PS and 25.88x price-to-book are rich: large-cap biotech peers with commercial products typically trade in the 4x-8x PS range, and the 25.88x PB is extreme for a company with negative ROE of -77.90%, implying the market is capitalizing pipeline optionality rather than current book value. The premium is partially justified by the antisense platform's breadth and the royalty stream from marketed drugs, but the 10.68x EV/Sales versus a sector norm closer to 5x-6x represents a roughly 80-100% premium that leaves little margin for execution error. Historically, Ionis's own PS ratio has been volatile and generally elevated: it reached 67.11x in Q3 2025 and 63.13x in Q4 2025 during periods of depressed revenue, versus 13.41x today, which on the surface looks like a discount to its own history — but that comparison is misleading because the prior spikes reflected revenue troughs, not valuation compression. More instructive is the PB ratio, which at 25.88x sits near the high end of its historical band (the stock traded at 9.39x PB in Q4 2024 and 10.07x in Q1 2025), suggesting the market is still assigning substantial value to intangible pipeline assets even after the 40% drawdown. The current valuation therefore embeds optimistic assumptions about commercial execution that the recent price action and negative cash flow trends do not yet support, making the risk-reward skewed toward disappointment unless revenue inflection becomes visible in the next two to three quarters.
PE
-33.2x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-52.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are acute: Ionis carries a debt-to-equity ratio of 5.35 and a debt ratio of 0.59, meaning total debt is roughly 80.6% of total capitalization. Free cash flow TTM is -$971.26 million, and Q1 2026 operating cash flow was -$792.82 million, including a -$730.12 million working capital swing. Cash at the end of Q1 2026 was only $173.38 million, down from $372.26 million at year-end 2025, and the company relied on $57.30 million of stock issuance and $752.82 million of investment maturities to fund operations. With R&D of $210.17 million and SG&A of $150.36 million in Q1 2026, and two independent launches ramping, losses may widen before they narrow, creating a structural dependence on external financing.
Market and competitive risks are significant: the stock trades at a price-to-sales ratio of 13.41x and EV/Sales of 10.68x, roughly 80-100% above the 5x-6x sector norm for commercial-stage biotechs, leaving little margin for execution error. The beta of 0.419 indicates low correlation with the broader market, so the -31.57% relative underperformance over one year is driven by idiosyncratic factors such as clinical and commercial news. Competitive pressure from Arrowhead Pharmaceuticals in the cardiovascular and metabolic space could erode market share for Tryngolza and Dawnzera. Additionally, the FDA approval of Zanvastro for the ultra-rare Alexander disease was viewed as commercially limited, highlighting the challenge of translating platform validation into significant revenue.
Worst-case scenario: a failed commercial launch of Tryngolza or Dawnzera, combined with a partner setback or pipeline failure, could trigger a breakdown below the 52-week low of $50.01. The analyst low target of $54.00 is already near the current price, but a more severe scenario could see the stock retest its historical lows, potentially down 30-40% from current levels. From the current price of $54.21, a drop to the 52-week low of $50.01 represents a 7.7% decline, but if the stock breaks below that support, the next psychological level could be $40, implying a 26% loss. The maximum drawdown of 40.15% over the past year shows the stock's vulnerability to sharp declines.
FAQ
The most severe risk is financial: free cash flow TTM is -$971.26 million, and cash reserves of $173.38 million are dwindling, with debt-to-equity at 5.35. Competitive risk from Arrowhead Pharmaceuticals could limit market share for Tryngolza and Dawnzera, and the ultra-rare market for Zanvastro limits its commercial potential. Macro risk is low given the beta of 0.419, but the stock is highly sensitive to company-specific news, as shown by the 30% single-session drop in July 2026. Company-specific risk includes pipeline failures or partnership setbacks, which could trigger a break below the 52-week low of $50.01.
The 12-month forecast has a base case (55% probability) of $65-$85, assuming steady commercial progress and analyst targets converging toward the average of $84.23. The bull case (25% probability) targets $84-$105, driven by successful launches and pipeline data, while the bear case (20% probability) targets $40-$54, reflecting commercial disappointments and cash burn. The most likely scenario is the base case, with the key assumption that Tryngolza and Dawnzera achieve modest market penetration without major competitive losses. The wide target range from analysts ($54 to $105) underscores the high uncertainty.
IONS appears overvalued on a price-to-sales basis, trading at 13.41x trailing and 10.68x EV/Sales, compared to the 5x-6x range for large-cap biotech peers. The price-to-book ratio of 25.88x is extreme given negative ROE of -77.90%, indicating the market is pricing in substantial pipeline success. However, the PEG ratio of 1.53 suggests that when growth is considered, the valuation is not egregiously expensive. The market is implying a more than tripling of revenue to $3.16 billion, which is an aggressive assumption that requires successful commercial execution. Relative to its own history, the PS ratio is lower than the 67.11x seen in Q3 2025, but that was due to revenue troughs, not valuation compression.
From a risk/reward perspective, IONS offers a potential 55.4% upside to the analyst average target of $84.23, but the downside risk is significant given the 40.15% maximum drawdown and negative free cash flow of -$971.26 million. The stock trades at a price-to-sales ratio of 13.41x, well above the sector average, and the commercial launches are still unproven. For risk-tolerant investors with a long-term horizon, it could be a speculative buy on weakness, but for most investors, a Hold rating is more appropriate until there is clearer evidence of revenue inflection. The biggest downside risk is a break below the 52-week low of $50.01, which could lead to further losses.
IONS is more suitable for long-term investment (minimum 2-3 years) given its early commercial stage, high volatility (beta 0.419 but idiosyncratic risk), and no dividend. The company's value will be realized as the pipeline matures and product revenue scales, but near-term earnings visibility is low, with negative EPS of -$0.56 in Q1 2026. Short-term trading is risky due to event-driven volatility, such as the 30% drop in July 2026. A suggested minimum holding period of 3 years allows time for commercial ramps and potential profitability, but investors should be prepared for dilution and cash burn.